News

Michael Rivers, MD, discusses the impact of Aetna's new policy requiring prior authorization for cataract surgery on ophthalmologists, their workflow, and patients.

The American Academy of Ophthalmology issued a guidance this week requiring all in-person attendees at its annual meeting Nov. 12-15 in New Orleans to show proof of COVID-19 vaccination.

Investigators study the systemic adverse physiologic effects of the virus that causes COVID-19.

The EURETINA 2021 Virtual Meeting is scheduled for Sept. 9 to 12, and retina specialists eagerly await the showcase of cutting-edge scientific developments.

Science fiction is quickly becoming science fact as a team of German scientists has developed a small, lab-grown brain cell cluster that developed fundamental eye structures.

A survey by Health Union sheds light on the issues patients are facing and can help ophthalmologists map out dry eye disease treatment strategies.

Patients can try different drops and dosing schedules to improve outcomes.

The American Society of Retina Specialists is gearing up for its 39th annual scientific meeting Oct. 8-12 at the JW Marriott San Antonio Hill Country Resort and Spa in San Antonio, Texas.

A study suggests that for the general population, evaluation for blepharoptosis should be done at 66 years of age, or at 63 and 70 years for males and females, separately.

A new study reveals that children of mothers with diabetes during pregnancy have an increased risk of eye problems.

Michael Rivers, MD, discusses how Modernizing Medicine's latest updates to its electronic health records EMA® system benefits both ophthalmologists and optometrists.

Scientists have developed a new approach that is less complex and does not require extracting the genetic RNA material of the virus.

The Academy has stepped up to speak out against the use of untested biosimilars in the eyes of patients amid a disruption in the drug supply chain.

GT005 designed to induce local production of recombinant complement factor I.

Aequus Pharmaceuticals, reVision Therapeutics announced this week that they will collaborate to develop a therapy for Stargardt disease.

Oxurion is currently recruiting patients for the Phase 2 clinical study of THR-687 in DME.

The company shared data from its two-year Phase III KITE trial and the one-year phase III KINGFISHER trial.

CAM’s regenerative healing means long-term relief and fewer visits to clinic.

Philip Rosenfeld, MD, PhD, presents results from a natural history study of patients that results in recognition of hypertransmission defects on en face OCT.

Cotargeted therapy could help combat inherited retinal diseases.

Special to Ophthalmology Times®

Tool for quantifying measures may predict outcomes for patients.

Substantial weight loss can help patients’ eye health, study results show.

The Research to Prevent Blindness (RPB), the Association of University Professors of Ophthalmology (AUPO) and an anonymous donor have recognized Donald Zack, MD, PhD, for ground-breaking contributions to the field of vision research.

According to Oculus, its Myopia Master saves space and can be mounted on a workstation or an ophthalmic table. The software is operated directly via an inbuilt display.

The company is evaluating topical cyclosporine to treat the signs and symptoms of dry eye disease.